SOURCE: SciClone Pharmaceuticals, Inc.

SciClone Pharmaceuticals, Inc.

July 31, 2009 17:30 ET

SciClone Pharmaceuticals to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

FOSTER CITY, CA--(Marketwire - July 31, 2009) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City. Friedhelm Blobel, Ph.D., SciClone's President and Chief Executive Officer, will present a corporate overview and business update on Wednesday, August 5, 2009 at 1:45 pm ET.

To access the live audio webcast of the presentation, please log on through a link located in the Investor Relations section of SciClone's website at www.sciclone.com.

About SciClone

SciClone Pharmaceuticals (NASDAQ: SCLN) is a profit-driven, global biopharmaceutical company with a substantial international business and a product portfolio of novel therapies for cancer and infectious diseases. SciClone is focused on continuing international sales growth, a cost-containing clinical development strategy, and expense management. ZADAXIN (thymalfasin/thymosin alpha 1) is sold in over 30 countries for the treatment of hepatitis B (HBV) and hepatitis C (HCV), certain cancers and as a vaccine adjuvant. SciClone's pipeline of drug candidates includes thymalfasin for stage IV melanoma, for which SciClone has reached agreement with the FDA on the design of a phase 3 trial; RP101 in a phase 2 trial for the treatment of pancreatic cancer; SCV-07 in a phase 2 trial for the delay of onset of severe oral mucositis in patients receiving chemoradiation therapy for the treatment of cancers of the head and neck; SCV-07 with a ready-to-initiate phase 2 trial for the treatment of HCV. SciClone has exclusive marketing rights to DC Bead™ in China, where the product is under regulatory review. The Company also has commercialization rights to an anti-nausea drug ondansetron RapidFilm™ in China and Vietnam, for which it is seeking regulatory approval. For additional information, please visit www.sciclone.com.